Lantheus (NASDAQ:LNTH) posted its earnings results on Thursday. The medical equipment provider reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.08, Briefing.com reports. Lantheus had a return on equity of 20.57% and a net margin of 3.51%. The firm had revenue of $66.01 million for the quarter, compared to analyst estimates of $55.77 million. During the same quarter in the prior year, the company earned $0.27 EPS. Lantheus’s revenue was down 23.0% on a year-over-year basis.
Shares of LNTH traded down $1.17 during trading hours on Friday, hitting $13.48. The stock had a trading volume of 1,600,707 shares, compared to its average volume of 578,579. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.41 and a current ratio of 2.37. The firm has a market cap of $535.91 million, a P/E ratio of 44.93 and a beta of 1.26. The company’s fifty day simple moving average is $14.59 and its 200 day simple moving average is $14.48. Lantheus has a 12-month low of $8.67 and a 12-month high of $27.12.
LNTH has been the topic of a number of recent analyst reports. Zacks Investment Research raised Lantheus from a “sell” rating to a “hold” rating in a research note on Friday, July 10th. Jefferies Financial Group initiated coverage on Lantheus in a research note on Monday, June 29th. They set a “buy” rating and a $29.00 price target on the stock. BidaskClub raised Lantheus from a “sell” rating to a “hold” rating in a research note on Tuesday, June 23rd. Finally, CJS Securities raised Lantheus from a “market perform” rating to an “outperform” rating in a research note on Tuesday, June 16th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $29.00.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Read More: What is a short straddle?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.